Table 1.
Parameters | Week 0 | Week 2 | Week 4 | Week 6 | |
---|---|---|---|---|---|
Body weight (g) | G1 Control | 36.26 ± 1.41 | 35.26 ± 1.47 | 35.34 ± 1.47 | 33.10 ± 0.93 |
G2 nHNK | 34.15 ± 1.35 | 35.03 ± 1.35 | 33.35 ± 1.45 | 32.71 ± 1.29 | |
G3 Cisplatin | 37.74 ± 0.93 | 35.46 ± 1.14 | 32.35 ± 1.45 | 29.18 ± 1.46* | |
G4 Cis/nHNK | 37.39 ± 1.71 | 35.28 ± 1.24 | 34.43 ± 0.84 | 33.55 ± 1.08 | |
Urine Osmolarity (mOsmol)/kg | G1 Control | 3100.0 ± 50 | 2516.7 ± 36 | 3140.0 ± 407 | 2856.3 ± 25 |
G2 nHNK | 3050.0 ± 351 | 2425.0 ± 70 | 2891.7 ± 436 | 3390 ± 590 | |
G3 Cisplatin | 3088.2 ± 456 | 1735.9 ± 78 | 1168.1 ± 83 | 1558.3 ± 183 | |
G4 Cis/nHNK | 2489.4 ± 347 | 1815.5 ± 198 | 1087.5 ± 75 | 1587.5 ± 188 | |
Serum BUN (mg/dl) | G1 Control | 20.84 ± 2.49 | 25.20 ± 2.35 | 21.6 ± 1.63 | 20.40 ± 1.91 |
G2 nHNK | 22.25 ± 3.10 | 24.25 ± 3.30 | 23.50 ± 3.90 | 18.25 ± 1.25 | |
G3 Cisplatin | 20.81 ± 1.79 | 20.00 ± 2.12 | 27.33 ± 3.18 | 47.00 ± 13.8* | |
G4 Cis/nHNK | 21.50 ± 4.00 | 20.75 ± 1.25 | 22.50 ± 4.17 | 18.00 ± 4.17 | |
Serum creatinine (mg/dl) | G1 Control | 0.160 ± 0.02 | 0.130 ± 0.03 | 0.130 ± 0.03 | 0.140 ± 0.04 |
G2 nHNK | 0.130 ± 0.03 | 0.130 ± 0.03 | 0.100 ± 0.00 | 0.130 ± 0.03 | |
G3 Cisplatin | 0.100 ± 0.00 | 0.130 ± 0.02 | 0.170 ± 0.02 | 0.230 ± 0.05* | |
G4 Cis/nHNK | 0.100 ± 0.00 | 0.143 ± 0.02 | 0.167 ± 0.03 | 0.100 ± 0.00 | |
Serum indoxyl sulfate (ppm) | G1 Control | 2.017 ± 0.27 | 3.043 ± 0.55 | 1.988 ± 0.35 | 2.600 ± 0.58 |
G2 nHNK | 2.302 ± 0.33 | 2.911 ± 0.61 | 1.810 ± 0.32 | 1.584 ± 0.23 | |
G3 Cisplatin | 2.021 ± 0.56 | 5.074 ± 2.08 | 7.694 ± 0.95* | 8.591 ± 0.51* | |
G4 Cis/nHNK | 2.397 ± 0.51 | 4.491 ± 1.64 | 5.256 ± 0.85 | 5.058 ± 0.95 |
1. Ctrl.: vehicle control (100 μL corn oil); nHNK: 5 mg/kg liposome-encapsulated honokiol alone, IP; Cisplatin: 10mg/kg cisplatin alone, IP; Cis/nHNK: 10 mg/kg cisplatin + 5 mg/kg Honokiol. 2. * indicates the G3 cisplatin group is significantly different (p < 0.05) from the G4 (treatment) cisplatin + honokiol group.